XML 65 R56.htm IDEA: XBRL DOCUMENT
v3.25.3

Liability Related to the Sale of Future Royalties and Milestones (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands |  | 1 Months Ended | 9 Months Ended |
--- | --- | --- | --- | ---
Jan. 19, 2018 | May 31, 2024 | Sep. 30, 2025 | Dec. 31, 2024
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |  |  |  |
Non-cash royalty revenue recognized |  |  | $ 77,535 |
Non-cash interest expense |  |  | 36,243 |
Fair value of the Purchaser Upsize Option |  |  |  | $ 69
HCR [Member] | GSK Agreements [Member] | Royalty Purchase Agreement [Member] |  |  |  |
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |  |  |  |
Percentage of purchase of worldwide rights to receive royalties | 100.00% |  |  |
Gross proceeds received for royalty rights | $ 190,000 |  |  |
Non-cash royalty revenue recognized |  |  | 77,500 |
Non-cash interest expense |  |  | $ 23,000 |
Effective annual interest rate |  |  | 13.80% |
Prospective effective annual interest rate |  |  | 23.90% |
Ligand Pharmaceuticals Incorporated [Member] | Common Stock [Member] |  |  |  |
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |  |  |  |
Warrants issued to purchase shars of common stock |  | 867,052 |  |
Warrants, exercise price |  | $ 17.3 |  |
Ligand Pharmaceuticals Incorporated [Member] | Royalty Purchase Agreement [Member] |  |  |  |
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |  |  |  |
Prospective effective annual interest rate |  |  | 21.40% |
Ligand Pharmaceuticals Incorporated [Member] | Purchase Agreement [Member] |  |  |  |
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |  |  |  |
Non-cash interest expense |  |  | $ 13,200 |
Effective annual interest rate |  |  | 21.00% |
Liability related to sale of future royalties and milestones |  |  | $ 63,879 |
Percentage of synthetic royalty on worldwide net sales of purchased assets |  | 2.625% |  |
Percentage reduction in amounts payable upon overall payments due exceeding specified return hurdle |  | 50.00% |  |
Percentage increase in synthetic royalty based on certain future events |  | 1.00% |  |
Consideration on sale of purchased assets gross |  | $ 75,000 |  |
Reimbursable expenses |  | 900 |  |
Time-based option to invest, additional amount |  | $ 25,000 |  |
Gross proceeds from purchase agreement |  |  | $ 75,000 |
Ligand Pharmaceuticals Incorporated [Member] | Covered License Agreements [Member] | Purchase Agreement [Member] |  |  |  |
Liability Related To Sale Of Future Royalties And Milestones [Line Items] |  |  |  |
Percentage of sale of development, regulatory and commercial milestone payments eligible to receive |  | 31.875% |  |
Percentage of royalties receipts |  | 18.75% |  |

X
- Definition Consideration on sale of purchased assets gross. + References No definition available. + Details
Name: | agen_ConsiderationOnSaleOfPurchasedAssetsGross
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Effective annual interest rate over life of royalty purchase agreement. + References No definition available. + Details
Name: | agen_EffectiveAnnualInterestRateOverLifeOfRoyaltyPurchaseAgreement
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Liability related to sale of future royalties and milestones. + References No definition available. + Details
Name: | agen_LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestones
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Liability related to sale of future royalties and milestones. + References No definition available. + Details
Name: | agen_LiabilityRelatedToSaleOfFutureRoyaltiesAndMilestonesLineItems
Namespace Prefix: | agen_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Non-cash interest expense related to sale of future royalties. + References No definition available. + Details
Name: | agen_NonCashInterestExpenseRelatedToSaleOfFutureRoyalties
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Noncash royalty revenue recognized. + References No definition available. + Details
Name: | agen_NoncashRoyaltyRevenueRecognized
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Percentage increase in synthetic royalty based on certain future events. + References No definition available. + Details
Name: | agen_PercentageIncreaseInSyntheticRoyaltyBasedOnCertainFutureEvents
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of purchase of worldwide rights to receive royalties. + References No definition available. + Details
Name: | agen_PercentageOfPurchaseOfWorldwideRightsToReceiveRoyalties
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of royalties receipts. + References No definition available. + Details
Name: | agen_PercentageOfRoyaltiesReceipts
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sale of development, regulatory and commercial milestone payments eligible to receive. + References No definition available. + Details
Name: | agen_PercentageOfSaleOfDevelopmentRegulatoryAndCommercialMilestonePaymentsEligibleToReceive
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of synthetic royalty on worldwide net sales of purchased assets. + References No definition available. + Details
Name: | agen_PercentageOfSyntheticRoyaltyOnWorldwideNetSalesOfPurchasedAssets
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage reduction in amounts payable upon overall payments due exceeding specified return hurdle. + References No definition available. + Details
Name: | agen_PercentageReductionInAmountsPayableUponOverallPaymentsDueExceedingSpecifiedReturnHurdle
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Proceeds from purchase agreement gross. + References No definition available. + Details
Name: | agen_ProceedsFromPurchaseAgreementGross
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Proceeds from royalties sold. + References No definition available. + Details
Name: | agen_ProceedsFromRoyaltiesSold
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Prospective effective annual interest rate over life of royalty purchase agreement. + References No definition available. + Details
Name: | agen_ProspectiveEffectiveAnnualInterestRateOverLifeOfRoyaltyPurchaseAgreement
Namespace Prefix: | agen_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Purchaser upsize option liability fair value disclosure. + References No definition available. + Details
Name: | agen_PurchaserUpsizeOptionLiabilityFairValueDisclosure
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Reimbursable expenses. + References No definition available. + Details
Name: | agen_ReimbursableExpenses
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Time-based option to invest, additional amount. + References No definition available. + Details
Name: | agen_TimeBasedOptionToInvestAdditionalAmount
Namespace Prefix: | agen_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Exercise price per share or per unit of warrants or rights outstanding. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Definition Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3 + Details
Name: | us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix: | us-gaap_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | dei_LegalEntityAxis=agen_HCRMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerDurationAxis=agen_GSKAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=agen_RoyaltyPurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=agen_LigandPharmaceuticalsIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=agen_PurchaseAndSaleAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ContractWithCustomerDurationAxis=agen_CoveredLicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |